Alto Neuroscience Inc.

ANRONYSE • USD
27.63 USD
↘ 1.91 (6.47%)🟢LIVE (AS OF 01:15 PM EST)
🟢Market: OPEN

Alto Neuroscience Inc. (ANRO) trades at $27.63 per share. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place ANRO at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$29.13
High?$29.66
Low?$26.98
Prev. Close?$29.54
Volume?302.9K
Avg. Volume?642.1K
VWAP?$28.04
Rel. Volume?0.47x
Bid / Ask
Bid?$27.59 × 600
Ask?$27.75 × 100
Spread?$0.16
Midpoint?$27.67
Valuation & Ratios
Market Cap?1.2B
Shares Out?40.1M
Float?27.7M
Float %?70.7%
P/E Ratio?N/A
P/B Ratio?4.00
EPS?-$2.37
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Employees
68
Market Cap
1.2B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-02-02
Address
650 CASTRO STREET, SUITE 450
MOUNTAIN VIEW, CA 94041
Phone: 773-255-5012
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
65
Short Sent.?
34
Piotroski F-Score?0/9Weak
Altman Z-Score?22.62Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.49%Squeeze Risk
Short Interest?5.7M
Days to Cover?10.5
Free Float27.7M
Avg Daily Volume540.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?18.12Strong
Quick Ratio?18.12Strong
Cash Ratio?17.90Strong
Debt/Equity?0.05Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
44
4.00FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-32.1%WEAK▾
ROA?
S&P
3
-29.2%WEAK▾
Cash Flow & Enterprise
FCF?$-79679000
Enterprise Value?$881.5M
Fundamentals ratios updated end of day